Page 7 - 2021_04-Haematologica-web

1129 Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study
Marie José Kersten et al.
https://doi.org/10.3324/haematol.2019.243238
Hemostasis
1138 Sec22b determines Weibel-Palade body length by controlling anterograde endoplasmic reticulum-Golgi transport Ellie Karampini et al.
https://doi.org/10.3324/haematol.2019.242727
Platelet Biology & its Disorders
1148 A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies Hanny Al-Samkari et al.
https://doi.org/10.3324/haematol.2020.251900
Letters to the Editor
1158 Concomitant constitutive LNK and NFE2 mutation with loss of sumoylation in a case of hereditary thrombocythemia Lukas Clemens Böckelmann et al.
https://doi.org/10.3324/haematol.2020.246587
1163 Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance Hannah Åbacka et al.
https://doi.org/10.3324/haematol.2020.246843
1167 Anemia and hemodilution: analysis of a single center cohort based on 2,858 red cell mass measurements Louis Drevon et al.
https://doi.org/10.3324/haematol.2020.249409
1172 Reveromycin A, a novel acid-seeking agent, ameliorates bone destruction and tumor growth in multiple myeloma Keiichiro Watanabe et al.
https://doi.org/10.3324/haematol.2019.244418
1178 Infrequent “chronic lymphocytic leukemia-specific” immunoglobulin stereotypes in aged individuals with or without low-count monoclonal B-cell lymphocytosis
Andreas Agathangelidis et al.
https://doi.org/10.3324/haematol.2020.247908
1182 Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
Fredrik Schjesvold et al.
https://doi.org/10.3324/haematol.2020.253450
1188 A homozygous missense variant in UBE2T is associated with a mild Fanconi anemia phenotype Laura Schultz-Rogers et al.
https://doi.org/10.3324/haematol.2020.259275
1193 Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma Maxime Fayon et al.
https://doi.org/10.3324/haematol.2019.242453
1198 Effect of post-consolidation regimen on symptomatic osteonecrosis in three DCOG acute lymphoblastic leukemia protocols Jenneke E. van Atteveld et al.
https://doi.org/10.3324/haematol.2020.257550
1202 Endoplasmic reticulum stress controls iron metabolism through TMPRSS6 repression and hepcidin mRNA stabilization by RNA-binding protein HuR
Audrey Belot et al.
https://doi.org/10.3324/haematol.2019.237321
haematologica Journal of the Ferrata Storti Foundation
Hodgkin Lymphoma
Haematologica 2021; vol. 106 no. 4 - April 2021 http://www.haematologica.org/